February 11, 2013 - Holaira, a medical device manufacturer based in Minneapolis, Minnesota, announced that it was able to successfully raise $10 million from investors in its latest financing round. According to a press release from the company, funds from the latest round will be used to pursue commercialization of its lung denervation system. The company’s lung denervation system is used for the treatment of chronic obstructive pulmonary disease (COPD).
In its press release, the company provided further detail about the Series C financing round. All of the company’s existing backers participated in the latest round. This includes investment groups and venture capitalists like Versant Ventures, Split Rock Partners, Morgenthaler Ventures and Advanced Technology Ventures.
Dr. Dennis Wahr is the CEO of Holaira. In prepared remarks, he said, "The completion of this financing signals continued confidence in the direction of our program to develop a system to enable a minimally invasive bronchoscopic treatment for COPD."
- Reduce Risk! Control Costs! Get to Market Faster! The Customer Solution Centre is Your Pathway to Successful Device Development. - Webcast
- Innovating within Cost Constraints to Get More Bang for Your Buck - Webcast
- Conformal Coatings for Tomorrow’s Medical Technologies - Webcast
- ISO80369 Standards Bring Changes to Medical Device Companies - Webcast
- Automation in Machining - Webcast
- How to Develop a Risk Based Biological Safety Evaluation Per New US FDA Guidance - Webcast